ClinicalTrials.gg
Not yet recruitingNCT06279494Updated Mar 21, 2024

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

A Phase 1/2 interventional study of Sirolimus and Abatacept in Acute Leukemia, Myelodysplastic Syndromes and Severe Aplastic Anemia, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Peking University People's Hospital · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing sirolimus in Myelodysplastic Syndromes — 3 open to participants now, 4 under way, none of them phase 3. Sirolimus · Myelodysplastic Syndromes.

Planned enrollment
12th of 15
6 · median 30
Started
2024
the only one that year
Phase 1/2
4 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
2 of 16
Peking University People's Hospital

Among the 16 studies testing sirolimus in Myelodysplastic Syndromes, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 1/2, and was the 15th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

3 of the 16 studies testing sirolimus in Myelodysplastic Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing sirolimus in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled. At present, the standard prophylaxis for GVHD is cyclosporine combined with methotrexate. However, calcineurin inhibitors (CNI) can cause some vital side effects, which are not tolerated by some patients. Therefore, this study aims to explore the safety and efficacy of Sirolimus in combination with Abatacept and Mycophenolate Mofetil for the prophylaxis of GVHD in patients with haplo-HSCT who are intolerant to calcineurin inhibitors.

03

Conditions studied

  • Acute Leukemia
  • Myelodysplastic Syndromes
  • Severe Aplastic Anemia

Keywords

  • Abatacept
  • Mycophenolate Mofetil
  • Sirolimus
  • Graft-versus-host-disease
  • Haploidentical
  • Calcineurin Inhibitor
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary disease: hematological (including acute leukemia, myelodysplastic syndromes), nonmalignant disorders (including severe aplastic anaemia)
  2. or intolerance to CNI

    1. (GFR) 60-89 ml/min/1.73m2 before transplantation or allergy to CNI
    2. Intolerance to CNI during conditioning or within +45 days post transplantation, such as CNI nephrotoxicity (creatinine higher than the ), uncontrolled hypertension, neurological toxicity, or other conditions deemed by physician to be inappropriate for CNI
  3. Receiving haplo- for the first time

Exclusion criteria

Exclusion Criteria:

  1. Allergy or intolerance to study drugs
  2. Active infection
  3. Active
  4. Transplantation-associated thrombotic microangiopathy
  5. Key organ dysfunction: liver injury (total more than 2 ) or heart injury (symptomatic heart failure or \<50%)
  6. (ECOG) score >2
  7. Expected survival time \<30 days
  8. Patients could not cooperate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Sirolimus+Abatacept+Mycophenolate mofetil (MMF)+anti-thymocyte globulin (ATG)

    Patients receiving haplo-HSCT who are intolerant to calcineurin inhibitors would receive Sirolimus+Abatacept+MMF+ATG (SAMA) for prophylaxis of aGVHD

    Drug: Sirolimus · Drug: Abatacept · Drug: MMF · Drug: ATG

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Grade 2-4 aGVHD within 100 days post transplantation

    Time frame: Participants will be followed for an expected average of 100 days post transplantation

Secondary outcomes

  1. Incidence of chronic GVHD (cGVHD) within 1 year post transplantation

    Time frame: Participants will be followed for an expected average of 1 year

  2. Incidence of thrombotic microangiopathy within 1 year post transplantation

    Time frame: Participants will be followed for an expected average of 1 year

Other outcomes

  1. Cumulative incidence of relapse

    Time frame: Participants will be followed for an expected average of 1 year

  2. Transplant-related mortality

    Time frame: Participants will be followed for an expected average of 1 year

  3. Overall survival

    Time frame: Participants will be followed for an expected average of 1 year

  4. Incidence of cytomegalovirus (CMV) and Epstein-Barr virus (EBV)

    Time frame: Participants will be followed for an expected average of 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Jun 2024, 3 months later.

Of 68 non-industry phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 142. This study's planned 3 months is below that.

Counting every sponsor, half of 109 studies reached it within 78 months; a quarter within 49 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 28, 2024
StartEst.
Mar 2024
Primary completionEst.
Jun 2024
CompletionEst.
Mar 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06279494
Responsible party
Xiao-Jun Huang (Prof., Peking University People's Hospital) — Principal investigator
First posted
Feb 28, 2024
Start date
Mar 2024 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Yuqian Sun, M.D.
Contact
sunyuqian83@hotmail.com
+86-10-88324577
Yuqian Sun
Contact
sunyuqian83@hotmail.com
+86-10-88324577
Xiao-Jun Huang
principal investigator · Institute of Hematology, Peking University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Abatacept

Start the discussion